<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=799546403794687&amp;ev=PageView&amp;noscript=1">
Blogs

School of Medicine News and Stories

Breast Cancer

Research    Breast Cancer

First-Year Medical Student Receives Research Award From the Endocrine Society 

Michael Boysen didn’t know that a research award from the Endocrine Society was in his future when he started working in the lab of University of Colorado Cancer Center member Matthew Sikora, PhD, last fall. But earlier this month, Boysen — a first-year medical student in the CU School of Medicine — got word that he is one of the recipients of the Endocrine Society’s Research Experiences for Graduate and Medical Students Award for 2022. In addition to $2,500 in research funding, the award includes participation in a summer research project and seminars on career development. 


Author Greg Glasgow | Publish Date May 31, 2022
Full Story

School of Medicine In the News

CPR

Hospitals struggle to serve growing number of children in need of intensive mental health treatment

news outletCPR
Publish DateJuly 25, 2024

In Colorado and across the nation, emergency departments at pediatric hospitals are overflowing with kids who need intensive mental health treatment.

More News
9News

Colorado kidney donor set to compete in her 12th Ironman competition

news outlet9News
Publish DateJuly 23, 2024

A little more than a month after the Olympics wrap up, women triathletes will be heading to the south of France for another competition on the global stage.

More News
Healthy Debate

Medical education’s next frontier: Space

news outletHealthy Debate
Publish DateJuly 18, 2024

In 1961, Yuri Gagarin became the first human in space. With every kilometre he ascended, he pushed the boundaries of human achievement and catalyzed a surge of interest in exploration, research, development – and medical innovation.

More News
Medscape

As GLP-1 Demand Goes Up, Access and Coverage Go Down

news outletMedscape
Publish DateJuly 18, 2024

Experts debating the pressing issue of how to prioritize patients in the increasingly common scenario of loss of access or insurance coverage for anti-obesity glucagon-like peptide 1 (GLP-1) receptor agonist drugs argued that comorbidities and obesity severity should strongly warrant continued coverage — while offering key strategies for getting and retaining approval from payers.

More News